An Investment Opportunity In The Growing Electrophysiology Market - BioSig Technologies

BioSig Technologies (BSGM) is a medical device company that is making significant developments in signal processing with its FDA approved PURE EP™ System. The purpose of this signal processing system is to help electrophysiologists more accurately diagnose and treat complex arrhythmias through improved targeting and visualization of low amplitude, high-frequency signals in order to increase the efficacy of the catheter ablation procedure.

This procedure is extremely important because roughly 1 in 4 people over the age of 40 are affected by this irregular heartbeat condition. The most successful way of treatment is through the catheter ablation procedure, however this is predicated on its success rate. Currently, the surgery is only 50-60% successful which poses a problem to the millions of patients who are in need of medical assistance. This is where PURE EP™ and BioSig Technologies step in. By increasing the clarity of the heart signal during procedures, BioSig is hoping to increase the success rate and meet the medical standard of care that many electrophysiologists are trying so hard to attain.

Here are some of the numbers. The global growth rate in EP Devices is projected to reach $7.4B in 2020, a 10.4% growth rate and an increase from its prior value of $4.5B in 2017. The 10-year strategic plan that BioSig Technologies has set up with the Mayo Clinic involves a collaborative work plan and projected commercialization in 2020. Mayo Clinic has even invested their own capital into the PURE EP™ system as well! On top of all of this, BioSig currently has important patents pending regarding their PURE EP™ system that have the potential of expansion into different industries. As a result of these factors, BioSig Technologies is set to ride a long road of growth, innovation, and market opportunity that its signal processing system and revolutionary electrophysiology advancements have paved.

- Matt Cerminaro